Page 1

Follow-Up Form Thymoma (THYM)

V4.01 112613

<u>Instructions</u>: The Follow-up Form is to be completed 12 months after a case enters the Biospecimen Core Resource (BCR). All information provided on this form includes activity from the "Date of Last Contact" provided on the TCGA Enrollment Form to the most recent date of contact with the patient. This form should only be completed by the Tissue Source Site if updated information can be provided to TCGA. Please direct any questions to the Clinical Outreach team at the BCR.

Please note the following definitions for the "Unknown" and "Not Evaluated" answer options on this form.

Unknown: This answer option should only be selected if the TSS does not know this information after all efforts to obtain the data have been exhausted. If this answer option is selected for a question that is part of the TCGA required data set, the TSS must complete a discrepancy note providing a reason why the answer is unknown.

Not Evaluated: This answer option should only be selected by the TSS if it is known that the information being requested cannot be obtained. This could be because the test in question was never performed on the patient or the TSS knows that the information requested was never disclosed.

_Completed Date: ____

	THE LINE AND A DECK	
Tissue Source Site (TSS):	TSS Identifier:	TSS Unique Patient Identifier:

Completed By (Interviewer Name on OpenClinica): ____

General Information # **Data Element Entry Alternatives** Working Instructions Indicate whether the patient is lost to follow-up, as defined by the ACoS Commission on Cancer. This only includes cases where updated follow-up information has not been collected within the past 15 months and all efforts to contact the patient have been exhausted (this includes reviewing the Social Is this Patient Lost to □ Yes 1* Security death index). If the patient is lost to follow-up, the Follow-up? 🗖 No remaining questions can be left unanswered. 61333 If the patient is **deceased** and a TCGA follow-up form has not yet been completed, the answer to this question should be "no," and the remaining applicable questions should be completed.

Follow-Up Information

The second sec				
#	Data Element	Entry Alternatives	Working Instructions	
2*	Adjuvant (Post- Operative) Radiation Therapy	☐ Yes ☐ No ☐ Unknown	Indicate whether the patient had adjuvant/ post- operative radiation therapy <i>for the tumor submitted for</i> <i>TCGA</i> . 2005312 If the patient did have adjuvant radiation, the Radiation Supplemental Form should be completed.	
3*	Adjuvant (Post- Operative) Pharmaceutical Therapy	☐ Yes □ No □ Unknown	Indicate whether the patient had adjuvant/ post- operative pharmaceutical therapy <u>for the tumor</u> <u>submitted for TCGA</u> . <u>3397567</u> If the patient did have adjuvant pharmaceutical therapy, the Pharmaceutical Supplemental Form should be completed.	
4*	Tumor Status (at time of last contact or death)	 Tumor free With tumor Unknown 	Indicate whether the patient was tumor/disease free at the date of last contact or death. 2759550	
5*	Vital Status (at date of last contact)	□ Living □ Deceased	Indicate whether the patient was living or deceased at the date of last contact. <u>2939553</u>	
6*	Date of Last Contact	//// (month)* (day) (year)*	If the patient is living, provide the date of last contact with the patient (as reported by the patient, medical provider, family member, or caregiver). <u>2897020</u> (month), <u>2897022</u> (day), <u>2897024</u> (year)	
7*	Date of Death	/// (month)* (day) (year)*	If the patient is deceased, provide the month of death. 2897026, (month) 2897028 (day), 2897030 (year)	

Page 2

Follow-Up Form Thymoma (THYM)

V4.01 112613

New Tumor Event Information Complete this section if the patient had a new tumor event. If the patient did not have a new tumor event (or if the TSS does not know) indicate this in the question below, and the remainder of this section can be skipped. Note: The New Tumor Event section on OpenClinica can be completed multiple times, if the patient had multiple New Tumor Events. **Working Instructions** # **Data Element Entry Alternatives** Indicate whether the patient had a new tumor event (e.g. metastatic, recurrent, or new primary tumor) after initial □ Yes treatment. New Tumor Event After 8* □ No 3121376 **Initial Treatment?** Unknown If the patient did not have a new tumor event or if this is unknown, the remaining questions can be skipped. Indicate whether the patient's new tumor event was a Locoregional Recurrence locoregional recurrence, a distant metastasis or a new primary Type of New Tumor tumor. A new primary tumor is a tumor with a different 9 Distant Metastasis Event histology as the tumor submitted to TCGA. □ New Primary Tumor 3119721 Indicate the site of this new tumor event. Lung 3108271 Bone Anatomic Site of New <u>10</u> Liver **Tumor Event** 🗖 Brain □ Other, (please specify) If the site of the new tumor event is not included in the Other Site of New provided list, describe the site of this new tumor event. 11 Tumor Event 3128033 If the patient had a new tumor event, provide the date of diagnosis for this new tumor event. 12* Date of New Tumor Event (month)* (day) (year)* 3104044 Using the patient's medical records, indicate whether the Additional treatment □ Yes patient had surgery for the new tumor event in question. for New Tumor Event: 13 □ No 3427611 Unknown Surgery Indicate whether the patient received radiation treatment for Additional treatment Yes this new tumor event. 14 □ No for New Tumor Event: 3427615 Unknown Radiation Therapy Indicate whether the patient received pharmaceutical treatment for this new tumor event. Additional treatment Yes 3427616 15 for New Tumor Event: □ No Note: Pharmaceutical treatment includes chemotherapy, Pharmaceutical Therapy Unknown immunotherapy, hormonal therapy, and targeted molecular therapy.

Page 3

Follow-Up Form Thymoma (THYM)

V4.01 112613

Time Intervals: The following questions are only to be answered if the Tissue Source Site is unable to provide the dates requested on this form. Please Note: Only provide interval data if you have received permission from the NCI to provide time intervals as a substitute for requested dates on this form.					
i	Has this TSS received permission from the NCI to provide time intervals as a substitute for requested dates on this form?	□ Yes □ No	Please Note : The time intervals must be recorded in place of dates where designated throughout this form if you have selected "yes" in the box. Provided time intervals must begin with the date of initial pathologic diagnosis (i.e., biopsy or resection).		
ii	Number of Days from Date of Initial Pathological Diagnosis to Date of Last Contact	days	Provide the number of days from the date the patient was initially diagnosed pathologically with the disease described on this form to the date of last contact. <u>3008273</u>		
iii	Number of Days from Date of Initial Pathological Diagnosis to Date of Death	days	Provide the number of days from the date the patient was initially diagnosed pathologically with the disease described on this form to the date of death <u>3165475</u>		
iv	Number of Days from Date of Initial Pathological Diagnosis to Date of New Tumor Event After Initial Treatment	days	Provide the number of days from the date the patient was initially diagnosed pathologically with the disease to the date of new tumor event after initial treatment. <u>3392464</u>		

Principal Investigator or Designee Signature

Print Name

___/ ____/ ____ ____ ___ Date (Month/Day/Year)